Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Athenex, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 2003-01-01

Employees: 280

Market Cap: -

Website: http://www.athenex.com

Clinical Trials

Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies

Phase 1

Recruiting

Conditions: B-cell Leukemia
DLBCL - Diffuse Large B Cell Lymphoma
ALL, Childhood
NHL, Relapsed, Adult
B-cell Lymphoma
ALL, Adult B Cell
CLL/SLL

Interventions: Genetic: KUR-502

First Posted Date: 2022-08-04

Last Posted Date: 2023-05-18

Lead Sponsor: Athenex, Inc.

Target Recruit Count: 36

Registration Number: NCT05487651

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸
OHSU - Knight Cancer Center, Portland, Oregon, United States
🇺🇸
Baylor College of Medicine, Houston, Texas, United States

A PK Study of Oraxol in Breast Cancer Patients

Phase 1

Completed

Conditions: Breastcancer

Interventions: Drug: Oraxol

First Posted Date: 2021-08-06

Last Posted Date: 2021-08-06

Lead Sponsor: Athenex, Inc.

Target Recruit Count: 24

Registration Number: NCT04993040

Locations: 🇨🇳
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China

Evaluate TCRT-ESO-A2 Autologous T Cells Expressing TCR Specific for NY-ESO-1 in Subjects With Advanced Solid Tumors

Phase 1

Withdrawn

Conditions: Advanced Solid Tumor

Interventions: Biological: TCRT-ESO-A2

First Posted Date: 2021-05-07

Last Posted Date: 2022-09-02

Lead Sponsor: Athenex, Inc.

Registration Number: NCT04878484

A Safety Study of Oraxol (HM30181 + Oral Paclitaxel) in Cancer Patients

Phase 2

Completed

Conditions: Solid Tumor

Interventions: Drug: Oraxol

First Posted Date: 2019-11-27

Last Posted Date: 2021-07-29

Lead Sponsor: Athenex, Inc.

Target Recruit Count: 44

Registration Number: NCT04180384

Locations: 🇦🇺
Monash Medical Centre, Clayton, Australia
🇳🇿
Auckland City Hospital, Auckland, New Zealand
🇳🇿
Wellington Regional Hospital, Wellington, New Zealand

and more 5 locations

An Extension Study to Provide Oraxol to Patients Who Completed KX-ORAX-007

Phase 1

Terminated

Conditions: Breastcancer

Interventions: Drug: Oraxol

First Posted Date: 2019-11-19

Last Posted Date: 2022-03-03

Lead Sponsor: Athenex, Inc.

Target Recruit Count: 11

Registration Number: NCT04168957

Locations: 🇨🇳
Taipei Medical University Shuang Ho Hospital, New Taipei City, Taiwan
🇨🇳
Taipei Veterans Generla Hospital, Taipei, Taiwan, 11217, Taiwan
🇨🇳
Taipei Medical University Hospital, Taipei, Taiwan

and more 2 locations

A Phase I Open-label Study for Subjects With Advanced Malignancies

Phase 1

Conditions: Advanced Solid Malignancies

Interventions: Biological: PT01 (Pegtomarginase)

First Posted Date: 2019-10-23

Last Posted Date: 2021-08-17

Lead Sponsor: Athenex, Inc.

Target Recruit Count: 62

Registration Number: NCT04136834

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

A Study to Determine the Bioequivalence of Oraxol in Cancer Patients Treated With Intravenous Paclitaxel

Phase 1

Completed

Conditions: Solid Tumor

Interventions: Drug: HM30181 methanesulfonate monohydrate plus oral paclitaxel capsules

First Posted Date: 2019-07-29

Last Posted Date: 2022-04-13

Lead Sponsor: Athenex, Inc.

Target Recruit Count: 42

Registration Number: NCT04035473

Locations: 🇳🇿
Auckland City Hospital, Auckland, New Zealand
🇨🇳
Lotung Poh-Ai Hospital, Ilan, Taiwan
🇳🇿
Wellington Regional Hospital, Wellington, New Zealand

and more 4 locations

Evaluate Eribulin ORA in Subjects With Solid Tumors

Phase 1

Terminated

Conditions: Solid Tumor

Interventions: Combination Product: Eribulin ORA

First Posted Date: 2019-07-09

Last Posted Date: 2025-04-13

Lead Sponsor: Health Hope Pharma

Target Recruit Count: 10

Registration Number: NCT04013217

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Evaluate Oral Topotecan With HM30181A Monotherapy in Patients With Advanced Malignancies

Phase 1

Completed

Conditions: Solid Tumor

Interventions: Drug: Oratopo

First Posted Date: 2019-06-17

Last Posted Date: 2022-02-16

Lead Sponsor: Athenex, Inc.

Target Recruit Count: 10

Registration Number: NCT03987685

Locations: 🇺🇸
HonorHealth Research Institute, Phoenix, Arizona, United States
🇬🇧
Sir Bobby Robson Cancer Trials Research Centre, Freeman Hospital, Newcastle, United Kingdom
🇬🇧
Cancer Research UK Clinical Trials Unit- The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

The Effect of Food on the Pharmacokinetics of Paclitaxel Administered Orally as Oraxol

Phase 1

Terminated

Conditions: Solid Tumor, Adult

Interventions: Drug: Oraxol

First Posted Date: 2019-03-27

Last Posted Date: 2023-05-22

Lead Sponsor: Athenex, Inc.

Target Recruit Count: 29

Registration Number: NCT03892018

Locations: 🇬🇧
The Beatson West of Scotland Cancer Care Centre, Glasgow, United Kingdom
🇬🇧
The Northern Institute for Cancer Care, Newcastle Upon Tyne, United Kingdom
🇬🇧
The Christie NHS Foundation Trust, Manchester, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy